4/9/2013

The FDA granted priority-review status to riociguat, an experimental oral soluble guanylate cyclase stimulator from Bayer, as a treatment for two forms of pulmonary hypertension. The agency is expected to finish its review in six months.

Full Story:
Fox Business

Related Summaries